Investigational drug · Phase 2
NKTR-255
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Locally Advanced or Metastatic Urothelial Carcinoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
8
Any phase or sponsor naming "NKTR-255"
First trial start
2022
Aug 17, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NKTR-255", any sponsor or status.
Conditions studied
As listed on its trial records.
- Locally Advanced or Metastatic Urothelial Carcinoma
Approved drugs for the same conditions: Bladder and urothelial cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "NKTR-255" as an intervention, largest first.
- A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)Pivotal-lookingActive, not recruiting
EMD Serono Research & Development Institute, Inc.Industry
NCT05327530 · 256 participants · Start Aug 17, 2022 · Primary completion Jun 20, 2025
Drug: Avelumab; Sacituzumab Govitecan (SG) and 3 more · For: Locally Advanced or Metastatic Urothelial Carcinoma
Sites: Coeur d'Alene, Idaho; Kansas City, Kansas; Baltimore, Maryland · 98 sites in all
- CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell MalignanciesActive, not recruiting
Stanford UniversityAcademic, hospital or other
NCT03233854 · 56 participants · Start Sep 1, 2017 · Primary completion Jun 20, 2023
Drug: Chimeric Antigen Receptor T-Cell Therapy; Cyclophosphamide and 2 more · For: B Acute Lymphoblastic Leukemia; CD19 Positive; Minimal Residual Disease and 1 more
Sites: Palo Alto, California
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT05632809 · 39 participants (planned) · Start Jan 10, 2023 · Primary completion Dec 31, 2027
Drug: NKTR-255; Durvalumab · For: Lung Cancer
Sites: Houston, Texas
Nektar TherapeuticsIndustry
NCT04136756 · 30 participants · Start Oct 7, 2019 · Primary completion Apr 24, 2023
Drug: NKTR-255; NKTR-255 Q21 and 2 more · For: Multiple Myeloma; Non-Hodgkin Lymphoma; Indolent Non-Hodgkin Lymphoma
Sites: Goodyear, Arizona; Duarte, California; San Francisco, California · 13 sites in all
Fred Hutchinson Cancer CenterAcademic, hospital or other
NCT05359211 · 27 participants · Start Dec 8, 2022 · Primary completion Sep 4, 2025
Drug: Cyclophosphamide; Fludarabine and 2 more · For: Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Recurrent Grade 3b Follicular Lymphoma and 6 more
Sites: Seattle, Washington
Nektar TherapeuticsIndustry
NCT04616196 · 25 participants · Start Oct 30, 2020 · Primary completion Mar 30, 2023
Drug: NKTR-255; Cetuximab · For: Head and Neck Squamous Cell Carcinoma; Colorectal Cancer
Sites: San Diego, California; San Francisco, California; Minneapolis, Minnesota · 6 sites in all
- NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell LymphomaPivotal-lookingTerminated
Nektar TherapeuticsIndustry
NCT05664217 · 15 participants · Start Feb 23, 2023 · Primary completion May 22, 2024
Drug: NKTR-255 at 1.5 µg/kg; NKTR-255 at 3.0 μg/kg and 1 more · For: Non-Hodgkin Lymphoma; Relapsed/Refractory Diffuse Large B-cell Lymphoma
Sites: Fairway, Kansas; Worcester, Massachusetts; St Louis, Missouri · 7 sites in all
- C-TIL051 in Non-Small Cell Lung CancerTerminated
AbelZeta Inc.Industry
NCT05676749 · 1 participants · Start Feb 29, 2024 · Primary completion Dec 30, 2025
Drug: C-TIL051 · For: Metastatic Non Small Cell Lung Cancer
Sites: New Orleans, Louisiana; Raleigh, North Carolina; Pittsburgh, Pennsylvania
Newest research
PubMed records naming it or its code names, newest first.
- NKTR-255, a polymer-conjugated IL-15, enhances CAR T cell therapy by engaging endogenous antitumor immunity.
Nutt WS, Marsh SA, Winschel M, et al. · Cancer Immunol Res 2026
- IL-15 superagonists for reprogramming the immunosuppressive microenvironment in gastrointestinal adenocarcinomas.
Choudhary N, Faiyazuddin M, Kamal R, et al. · Cancer Lett 2026
- Circumventing Ewing sarcoma tumor microenvironment resistance by IL1RAP CAR-modified TGFβ1-imprinted natural killer cells in combination with IL-15 agonist and anti-GD2 antibody.
Luo W, Zhang HF, Li W, et al. · J Immunother Cancer 2026
- CXCL10-induced chemotaxis of ex vivo-expanded natural killer cells combined with NKTR-255 enhances anti-tumor efficacy in osteosarcoma.
Eguchi S, Luo W, Zhu H, et al. · Mol Ther Oncol 2025
- NKTR-255, a polymer-conjugated IL-15, synergizes with CAR-T cell therapy to activate endogenous anti-tumor immunity and improve tumor control.
Nutt WS, Kluesner MG, Bingham E, et al. · bioRxiv 2025
- NKTR-255 enhances complete response following CD19 CAR T-cell therapy in patients with relapsed/refractory large B-cell lymphoma.
Ahmed S, DiPersio J, Essell J, et al. · Blood Adv 2025
Also in development for Locally Advanced or Metastatic Urothelial Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.